ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 632,71
0,00%
Dow Jones
40 211,72
0,53%
DAX
18 590,89
-0,95%
Brent Oil
83,785
-0,66%
Bitcoin
63 843,52
-1,55%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Portola Pharmaceuticals Inc (PTLA)

  7. Portola Pharmaceuticals Inc (PTLA) Actualités

PTLA

Portola Pharmaceuticals (PTLA)

Portola Pharmaceuticals Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:PTLA
DateHeureSourceTitreSymboleSociété
18/05/201714h00GlobeNewswire Inc.Portola Pharmaceuticals Announces Phase 2a Safety and Efficacy Cerdulatinib Data to be Presented at the European Hematology A...NASDAQ:PTLAPortola Pharmaceuticals Inc
09/05/201714h00GlobeNewswire Inc.Portola Pharmaceuticals Announces Cerdulatinib Data to be Presented at the International Conference on Malignant Lymphoma (IC...NASDAQ:PTLAPortola Pharmaceuticals Inc
09/05/201712h10Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:PTLAPortola Pharmaceuticals Inc
08/05/201722h36GlobeNewswire Inc.Portola Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Corporate UpdateNASDAQ:PTLAPortola Pharmaceuticals Inc
08/05/201722h06Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:PTLAPortola Pharmaceuticals Inc
01/05/201714h00GlobeNewswire Inc.Portola Pharmaceuticals to Announce First Quarter 2017 Financial Results and Host Conference Call on Monday, May 8NASDAQ:PTLAPortola Pharmaceuticals Inc
24/04/201723h11Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:PTLAPortola Pharmaceuticals Inc
24/04/201722h56Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:PTLAPortola Pharmaceuticals Inc
15/04/201700h45Edgar (US Regulatory)Amended Statement of Changes in Beneficial Ownership (4/a)NASDAQ:PTLAPortola Pharmaceuticals Inc
11/04/201722h35Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:PTLAPortola Pharmaceuticals Inc
21/03/201722h23Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:PTLAPortola Pharmaceuticals Inc
16/03/201718h53Edgar (US Regulatory)Confidential Treatment Order (ct Order)NASDAQ:PTLAPortola Pharmaceuticals Inc
07/03/201722h05GlobeNewswire Inc.Portola Pharmaceuticals Announces Betrixaban and AndexXa™ (andexanet alfa) Presentations at ACC.17NASDAQ:PTLAPortola Pharmaceuticals Inc
01/03/201723h19Edgar (US Regulatory)Annual Report (10-k)NASDAQ:PTLAPortola Pharmaceuticals Inc
01/03/201714h00GlobeNewswire Inc.Portola Pharmaceuticals to Present at Two Upcoming Investor ConferencesNASDAQ:PTLAPortola Pharmaceuticals Inc
28/02/201722h05GlobeNewswire Inc.Portola Pharmaceuticals Reports Fourth Quarter and Year-End 2016 Financial Results and Provides Corporate UpdateNASDAQ:PTLAPortola Pharmaceuticals Inc
21/02/201714h00GlobeNewswire Inc.Portola Pharmaceuticals to Announce Fourth Quarter and Year-End 2016 Financial Results and Host Conference Call on Tuesday, F...NASDAQ:PTLAPortola Pharmaceuticals Inc
14/02/201717h47Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:PTLAPortola Pharmaceuticals Inc
14/02/201700h27Edgar (US Regulatory)Annual Statement of Changes in Beneficial Ownership (5)NASDAQ:PTLAPortola Pharmaceuticals Inc
10/02/201717h16Edgar (US Regulatory)Schedule 13gNASDAQ:PTLAPortola Pharmaceuticals Inc
08/02/201714h00GlobeNewswire Inc.FDA Informs Portola Pharmaceuticals at Mid-Cycle Review for Betrixaban That It Has Not Identified Issues that Require an Advi...NASDAQ:PTLAPortola Pharmaceuticals Inc
03/02/201714h00GlobeNewswire Inc.Portola Pharmaceuticals Signs $150 Million Royalty Agreement with HealthCare Royalty Partners for Development and Commerciali...NASDAQ:PTLAPortola Pharmaceuticals Inc
03/01/201714h00GlobeNewswire Inc.Portola Pharmaceuticals to Webcast Corporate Update on January 10, 2017NASDAQ:PTLAPortola Pharmaceuticals Inc
23/12/201620h12GlobeNewswire Inc.Portola Pharmaceuticals Announces FDA Accepts New Drug Application for Priority Review and EMA Validates Marketing Authorizat...NASDAQ:PTLAPortola Pharmaceuticals Inc
19/12/201614h00GlobeNewswire Inc.Portola Pharmaceuticals Enters into $50 Million Loan Agreement with Bristol-Myers Squibb and Pfizer for Continued Development...NASDAQ:PTLAPortola Pharmaceuticals Inc
28/11/201614h00GlobeNewswire Inc.Portola Pharmaceuticals Announces AndexXa™ (andexanet alfa), Betrixaban and Cerdulatinib Data to be Presented at 2016 Ameri...NASDAQ:PTLAPortola Pharmaceuticals Inc
14/11/201622h15GlobeNewswire Inc.Portola Pharmaceuticals Announces Three Phase 3 APEX Substudy Results Showing Further Benefits of Treating Acute Medically Il...NASDAQ:PTLAPortola Pharmaceuticals Inc
07/11/201622h05GlobeNewswire Inc.Portola Pharmaceuticals Reports Third Quarter 2016 Financial Results and Provides Corporate UpdateNASDAQ:PTLAPortola Pharmaceuticals Inc
07/11/201614h00GlobeNewswire Inc.Portola Pharmaceuticals Announces New APEX Study Sub-Analyses Data to be Presented at American Heart Association Scientific S...NASDAQ:PTLAPortola Pharmaceuticals Inc
02/11/201613h00GlobeNewswire Inc.Portola Pharmaceuticals to Present at the Credit Suisse 25th Annual Healthcare ConferenceNASDAQ:PTLAPortola Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:PTLA

Dernières Valeurs Consultées

NASDAQ
SCOBU
ScION Tech Growth II
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés